Background: Obliterative bronchiolitis (OB) is the most numerous important cause of long-term morbidity and mortality in lung transplant recipients.
Background: Obliterative bronchiolitis (OB) is the most numerous important cause of long-term morbidity and mortality in lung transplant recipients, and probably ends from alloimmune airway injury. Bronchiolitis obliterans syndrome (BOS) defined as a staged decline in pulmonary function, is the clinical correlate of OB
Objective: Evaluation of the risk and severity of BO forward the basis of the incompatibility of donor and recipient human leukocyte antigen (HLA) molecules
Design: Retrospective cohort study
Setting: Large university hospital.
Participants: Lung transplant recipients between January 1990 and January 2000
Measurements: We determined the BO stage using internationally promulgated guidelines with a minor modification upon all recipients at their 4-year transplant anniversary. Recipients whose graft function had deteriorated or who died appropriate to causes other than BO were exclud from the close attention HLA loci mismatches and other covariables, including recipient age, donor age, cytomegalovirus (CMV) mismatch, hyemal ischemic time, use of cardiopulmonary bypass, ventilatory days, episodes of acute rejection and CMV pneumonitis, mean long tray cyclosporin A (CsA) level, episodes of subtherapeutic CsA on a levels and histopathology of OB and diffuse alveolar damage were jot downed into the analysis of BO predictors.
Results: Sixty-four patients met the inclusion and exclusion criteria of the meditation at the 4-year posttransplant time point. In univariate analyses, the number of combined HLA-A and HLA-B mismatches was forcibly associated with the stage of BO at 4 years (p = 0002) This association remained significant after the inclusion of other potential risk factors for BO in multiple linear regression standards Pretransplant and posttransplant proportional singles models confirmed that the increasing number of combined HLA-A and HLA-B mismatches increased the overall severity of BO (adjusted redundants ratio, 1.84 [p = 0035] v 169 [p = 0067] respectively). A trending toward significance was seen with HLA-DR mismatching (p = 017)
Conclusions: The order of HLA class I mismatching between donors and recipients predisposes lung transplant recipients to the progressive growth and severity of BOS.
guide words: bronchiolitis obliterans syndrome; human leukocyte-associated antigen; lung transplant; obliterative bronchiolitis
Abbreviations: AOR = adjusted unevens ratio; BOS = bronchiolitis obliterans syndrome; CMV = cytomegalovirus; CPB=cardiopulmonary bypass; CsA = cyclosporin A; DAD = diffuse alveolar damage. HLA = human leukocyte antigen; OB = obliterative bronchiolitis; PTLD = posttransplant lymphoproliferative disorclers
**********
Lung transplantation has become an established therapeutic option for patients with end-stage lung disease. Despite a reasonable 1-year posttransplant actuarial survival rate of 735% the 5-year actuarial survival rates of single and double lung transplants are 451% and 500% respectively, (1) and are not as auspicious as those rates achieved after the transplantation of other solid organs. Obliterative bronchiolitis (OB) which is generally considered to be synonymous with chronic lung allograft rejection, is the greatest in quantity significant cause of long-term morbidity and mortality. (1) The standardization of nomenclature and staging of chronic lung allograft dysfunction proper to OB has been bring to maturityed (2) and updated. (3) The clinical entity of OB has been confineed bronchiolitis obliterans syndrome (BOS) and is staged using fractional declines in the [FEVsub1] from baseline values. one time the presence of BOS is established, however, pulmonary function losse rarely are regained, and progressive graft deterioration and death are universal despite therapeutic efforts. (1) Identifying the risk factors will guide that will be research in the areas of pathogenesis and therapy for BO Meanwhile, mitigating the risk factors for BO is essential to improve lung transplant outcomes
Human leukocyte antigen (HLA) matching of donors and recipients clearly improves issues after hematopoietic cell, kidney, and heart transplantation. Several smaller studies and, a more fresh larger study have noted an association between HLA mismatching and lung graft survival, (45) patient survival (67) cute rejection, (89) and the personality or absence of BOS. (10-13) However, the association between HLA mismatches and BO has been controversial in the literature, as there are more studies showing no association than those finding an association. (710-17) As a consequence the most recent consensus from the International Society of Heart and Lung Transplantation does not recognize HLA mismatching as an established risk factor for BO (3)
The conflicting inferences on this subject are to be ascribed predominantly to the small sample sizes and methodological differences among studies. Many previous analyses have largely viewed patients with BO as being homogeneous, irrespective of the time of assault severity, or progression of BO or were limited according to an insufficient length of follow-up time. For example, a patient may be staged as BO 0 at 4 month posttransplant and in addition the same patient may be at BO stage 3 at 2 years posttransplant. The duration of follow-up in such a case would affect the analysis of any predictor of BO We hypothesized that immune answers are involved in the progress to maturity of BOS and that mismatched donor HLA alloantigens provide the immunologic stimulus that increases the advent and, more importantly, the severity of BO Using the same cohort, we studied the associations between other pretransplant and posttransplant risk factors and the severity of BO The independent risk factors for the severity of BO were integrated into pair proportional odds models, one of which included pretransplant and posttransplant variables and the other of which included barely pretransplant variables. These models provided us with invaluable tools with which to predict objectively the disclosure and severity of BOS in lung transplant recipients.
...